Beyond chemotherapy: targeted therapies in ovarian cancer

被引：404

作者：

Yap, Timothy A.

Carden, Craig P.

Kaye, Stan B. ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England

来源：

NATURE REVIEWS CANCER | 2009年 / 9卷 / 03期

基金：

美国国家卫生研究院;

关键词：

PHASE-II TRIAL; ENDOTHELIAL GROWTH-FACTOR; PRIMARY PERITONEAL CARCINOMA; PLATINUM-RESISTANT OVARIAN; RECEPTOR INHIBITOR SU6668; TYROSINE KINASE INHIBITOR; CIRCULATING TUMOR-CELLS; ADVANCED-STAGE OVARIAN; DNA-REPAIR DEFECT; BRCA MUTANT-CELLS;

D O I：

10.1038/nrc2583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.

引用

收藏

页码：167 / 181

页数：15

相关论文

共 165 条

[1] Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].

Agarwal, R ;

Kaye, SB .

NATURE REVIEWS CANCER, 2003, 3 (07) :502-516

[2] Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) [J].

Alberts, D. S. ;

Liu, P. Y. ;

Wilczynski, S. P. ;

Jang, A. ;

Moon, J. ;

Ward, J. H. ;

Beck, J. T. ;

Clouser, M. ;

Markman, M. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (04) :784-788

[3] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[4] HER pathway gene expression analysis in a phase II study of pertuzumab plus gemcitabine vs. gemcitabine plus placebo in patients with platinum-resistant epithelial ovarian cancer [J].

Amler, L. ;

Makhija, S. ;

Januario, T. ;

Matulonis, U. A. ;

Strauss, A. ;

Dizon, D. S. ;

Sliwkowski, M. X. ;

Dolezal, M. ;

Tong, B. ;

Paton, V. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[5]

[Anonymous], 2006, J CLIN ONCOLOGY M S

[6]

Arboleda MJ, 2003, CANCER RES, V63, P196

[7] Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse [J].

Armstrong, D. K. ;

Bicher, A. ;

Coleman, R. L. ;

Gibbon, D. G. ;

Glenn, D. ;

Old, L. ;

Senzer, N. N. ;

Schneeweiss, A. ;

Verheijen, R. H. ;

White, A. J. ;

Weil, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[8]

ARMSTRONG DK, 2008, J CLIN ONCOL, V26, P1

[9] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[10] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

← 1 2 3 4 5 6 7 8 9 10 →